Shaping the Future of Work | The ILR School | Cornell University – Cornell University | ILR School

A new social contract is possible if workers, business, labor, education and government work together, Lee Dyer and Tom Kochan say in the new edition of their book.

A new edition of "Shaping the Future of Work: A Handbook for Action and a New Social Contract" by Lee Dyer, ILR emeritus professor of Human Resource Studies, and MIT Professor Thomas A. Kochan is a call to action to develop good jobs and strong business while overcoming social and economic divisions.

According to Routledge, which published the book in November, it provides a clear roadmap for the roles workers and leaders in business, labor, education, and government must play in building a new social contract for all to prosper.

Dyer taught at ILR for 45 years and is a research fellow at ILRs Center for Advanced Human Resource Studies. Kochan is the George M. Bunker Professor of Management at the MIT Sloan School of Management. He taught at ILR before joining MITs faculty.

Dyer recently discussed the book for this story:

How did the social contract between workers and employers evolve in the post-World War II years?

It evolved organically, thanks to the confluence of several favorable conditions: (1) U.S. corporations were dominant globally after the war and many of the bigger ones were highly regulated, so conditions werent as competitive as they are now, (2) executives had a greater sense of social responsibility than they do now (perhaps because of condition 1), (3) unions were powerful and negotiated very favorable contracts which other companies often adopted, and (4) New Deal labor laws and policies were in effect and effectively enforced, and for example, facilitated the large and powerful unions.

How and when did the social contract fall apart?

Starting in the mid- to late-70s, companies began facing more competitive conditions and became enamored with and empowered by Milton Friedmans admonition to pay attention to profits and stockholders and dont worry about any obligations to employees or other stakeholders. The labor movement steadily declined in membership and power, in part because of tougher anti-union stances by management, and thus found it tougher to resist the executive profit grab. Reagans mass firing of the countrys air traffic controllers in the early 80s jump-started this effort. From then until now, right-wing pressures for stockholder preeminence and less government regulation of business kept eating away at workers rights, while creating conditions favoring the flow of riches to the already rich. Do you see opportunity for a new social contract? Why?

Yes, when Im being optimistic. The Business Roundtable just came out with a new statement on the purpose of the corporations, which adopted a stakeholder, rather than pure stockholder, preeminence point of view. This was in the context of making the economy work for everyone including workers. President Biden certainly shares this view, as do union leaders, and other labor advocates. So, there is some commonality to work from. Of course, there are differences of opinion about the meaning of this phrase. Some question whether corporate types even really believe in it. But, if there is a common base to work from, negotiations are possible.

Has the pandemic opened the door to a shift in the workplace where there will be more focus on equality and more flexibility for workers?

Yes. It certainly has highlighted the ways in which the economy isnt working for everyone (to those who will pay attention). So, there is hope. But, again, unless there are forums for pursuing a new social contract, it will be easy for the major players to just talk or worse, endlessly and futilely argue with each other.

You and your co-author, Tom Kochan, say we have the ability to shape the work of the future by harnessing the power of new technologies. Who will lead that charge?

MIT has a good start on this with its university-wide Task Force on Work of the Future. The basic position is that technology is too important to be left entirely to the technologist, particularly when it comes to basic designs and workplace applications. The task force and others advocate partnerships between technologists and users, each to inform the other, so that by and large, we get technologies that augment work, rather than replace it.

What strategies will business have to adopt to create good jobs and what do you expect those good jobs to look like?

They have to take the Business Roundtable stakeholder view seriously, to learn to view workers as valuable resources to be used to their full capacities rather than simply as costs to be eliminated or at least minimized, and to get out from under Wall Streets relentless pressure for short-term profits.

Some define good jobs as those they pay a decent (e.g., living) wage. Others, including Tom and I, take a broader view also emphasizing the importance of interesting work, investments in workers skills and futures, fair treatment, diversity and inclusion, and the need for worker voice, such as input into important decisions and an unfettered right to protest injustices, at all levels, from the boardroom to the shop floor.

What can individual workers do to contribute to a new way of thinking about work?

Available evidence suggests that most workers are already there. We cite evidence from the students in our courses, for example, to show that they not only know the difference between good and bad jobs, but also fully expect to have good ones. Tom has gathered extensive data on the voice issue. The problem is that individual workers lack power; they need the power of unions and other worker advocacy groups behind them.

Life-long learning will be key if a new social contract is to be successful. Explain how learning will be driven.

Our entire educational infrastructure from pre-school to retirement needs to be rethought because its not working. The U.S. spends more and gets less from its educational system than any other advanced country. The weakest link in the process occurs after workers finish their formal education and begin working. Employers do far less training than they used to and much of what they do is concentrated on managers and potential executives. Efforts by universities and outfits like Coursera are hit and miss.

Technology and other forces are going to keep changing the nature of work. We need to figure out how to keep workers skills in line with the evolving demand. Tom and I advance a few thoughts on the matter, but certainly dont claim to have all the answers. Once again, though, if business leaders, labor leaders, educator and public policymakers started working on a new social contract, they could make some meaningful progress.

How can government support a better future for work?

Governments role over the past 40 years has mostly been in the opposite direction, but President Biden has a bunch of ideas for changing that. He cant go it alone, though. Thats why Tom and I keep coming back to the need for business leaders to work with, rather than against, him on this, along with labor leaders and educators.

What role will organized labor play?

It could play an important part, especially if it would work on a new social contract with the other key players taking a broader view of making the economy work for all workers and not just their members.

Also, it is essential to take a broader view of labor; much worker advocacy takes place outside traditional labor unions in what some refer to as alt-labor organizations. The ad hoc community organizations that have sprung up around the country in support of the $15 an hour minimum wage is just one example of this.

Building a better workplace is a complex undertaking. Where do you expect leaders to emerge? Are there certain sectors or nations that are already building a reimagined future? What can we learn from them?

There are actually quite a few experiments of various kinds going on at the community, sector and state levels. The most noticeable is around various versions of apprenticeship training involving community colleges, labor unions and employers. We cite quite a few of these in the book. But, there still needs to be an umbrella group at the national level involving all the key players to consolidate and push the best ideas that spring up from below. We could learn a lot from some of the Nordic and Scandinavian countries, but suggestions along this line often evoke knee-jerk cries of socialism.

A more equitably shared prosperity how long will it take to build that and what will it look like?

Well, its taken 40-plus years to tear down the last one. But, I like to think with a concerted effort in the other direction, a lot of what has been learned in the past few years could be put to good use to speed up the effort. But, its a complex world, so well see. It will be a situation in which the economy is creating the greatest good for the greatest number and no one is getting hurt.

Whats the most important thing you want people to learn from your book?

That the future of work isnt ordained by external forces (globalization, technology, financialization, etc.). We will get the future we decide to have. We can decide to continue on the current path that brought us the most unequal distribution of income and wealth in the developed world. Or, we can decide to turn things around. A good start would be for the key players in the system business leaders, labor leaders, educators and public policymakers to get to work on building a new social contract. Read the book and then get with it.

See original here:

Shaping the Future of Work | The ILR School | Cornell University - Cornell University | ILR School

Cancer gene sequencing and an unexpected transmission – Health Report – ABC News

The New England Journal of Medicine has a potentially disturbing report from Japan of two little boys, one aged two, the other aged six, diagnosed with lung cancer (they are not related) whose mothers had cervical cancer. Genome sequencing found that the tumours in the kids, although they seemed very different from the mothers, were genetically related to their mum's tumour. The assumption was that cancer cells had spread to the boys in the physical process of being born.

Dr Alison Brand is director of gynaecological oncology at Westmead Hospital in Sydney. Welcome to the Health Report, Alison.

Alison Brand: Thanks for having me.

Norman Swan: So have you ever heard of this before?

Alison Brand: No, I had not heard of this before this and, I have to say, it's virtually unheard of, and the New England Journal of Medicine, which is the peak journal in medicine to publish a case report. So you know if they've published this case report they have really examined the data very closely to verify that it is true. And I think we have to do believe some of it because it has been published in the New England Journal of Medicine.

Norman Swan: Let me just divert from the core story here, which is about cervical cancer moving to the kids and getting into their lungs. You're a gynaecological surgeon, you do a lot of surgery, what's the story with gynaecological seeding and surgery? There has been a lot of discussion about that, whether in fact you can spread cancer with surgery itself.

Alison Brand: The old wives' tale was that once you open up the belly and let the air in, then the cancer just spreads terribly, and of course we know that's not true. That really came from the fact that when patients had operations many years ago, they found cancer but then they couldn't do much about it, there was no chemotherapy or there was no radiotherapy. So really this whole business of surgery spreading cancer is probably not true at all. We do know that cancer from the mum can sometimes cross the placenta and get into babies, but that's usually haematologic malignancies.

Norman Swan: So it's leukaemia.

Alison Brand: Leukaemia, that's right, and otherand basically the babies then have widespread disease because it got into their bloodstream and then went throughout the body. These particular two case reports are really unusual because it doesn't look like it came transplacentally or through the placenta, it looks like it came as the baby has passed through the birth canal, and landed in the lung, which is the kind of closest place that the babies could breathe in some of the cells that were in the vagina as they pass through the birth canal.

Norman Swan: And because of that you wouldn't think it was human papilloma virus related, which is the cause of cervical cancer, because it was the actual tumour itself that got transmitted.

Alison Brand: Yes, that's right, although we haven't often thought that cancer is catching. I think that's the one thing that we've said; you can't touch someone who has cancer and then catch it, and in many ways you catch lots of viruses, and women can pass their HPV infections in some rare cases to their babies. And so this is unusual in that the cancer has really been caught from the mother and that's highly unusual.

I guess when we look at this we have to look atas we examine any reports, we have to say is this biologically plausible, and I guess in rare cases it is biologically plausible, although you mostly expect that the tumour cells on the top of tumours are really those ones that are often non-viable or not living and therefore can't attach to something and grow there. But I think that the next generation sequencing that they have done here really suggests to us that maybe there is some truth to all of this, albeit rare, rare, rare.

Norman Swan: Is it routine to screen for cervical cancer in pregnancy?

Alison Brand: It is routine that patients should have had a recent screen prior to their pregnancy, and if they haven't, to have one done during pregnancy. What you have to remember though, Norman, is certainly the mother of the first patient had had a normal cervical screen seven months prior to delivering her baby, and it's important because she had a very rare neuroendocrine tumour, so a very rare type of cervical tumour that probably wouldn't have been picked up by screening anyway. But those are very rare tumours, and the vast majority of cervical cancers can be picked up by screening, and certainly are much better picked up by the new screening test that we have that looks at HPV presence.

Norman Swan: And before we go, just tell usbecause the screening program has changed, it now happens every five years if I remember rightly, and you are checking for HPV. So, just give us a very brief outline of the screening program now.

Alison Brand: So it used to be that we looked at the cells on the cervix to check to see whether or not they had precancerous changes. That had up to a 30% false negative rate, and therefore we had to screen more often to make sure that we didn't miss anything. Now we check by looking at what we call high risk HPV virus, which is human papilloma virus, which is known to cause cervical cancer, and we check for that high risk HPV, and because the test is so sensitive, then if there is a negative test, we only need to do the test every five years. And I think the take-home message here for women who are pregnant is that we shouldn't worry so much about giving your baby cancer from you, what we should really worry about is making sure that we prevent cancer in the first place by having regular screening and, if eligible, making sure your boys and girls have vaccinations.

Norman Swan: Alison, thank you for joining us.

Alison Brand: Thank you.

Norman Swan: Dr Alison Brand is director of gynaecological oncology at Westmead Hospital in Sydney.

See original here:
Cancer gene sequencing and an unexpected transmission - Health Report - ABC News

Covid-19 disrupts plans of medical school students and young health care workers – Vox.com

Marisa Reynolds spent months anticipating the pandemics effects on her final year of medical school. Her clinical clerkship was delayed, and her research stint at the National Institutes of Health was canceled. So were parts of the fourth-year board exam Reynolds expected to take and the option to participate in an out-of-state clerkship crucial opportunities students are typically afforded before applying for post-graduate residency programs.

The pandemic is not something in our control, but its frustrating, to put it lightly, that it will have these long-term effects on our careers and lives for years to come, said Reynolds, a Michigan State medical student seeking out internal medicine residencies. Its a high-stakes process, and despite the logistical challenges that affected the quality of Reynoldss and her peers application such as late test scores and a shortened residency interview timeline there is no option to try again next year.

She is also worried that the pandemic has made the process less equitable: Some students didnt receive as many interviews as others, and there was limited time to make a strong impression on their program of choice.

Youre basically entering a career marriage for the next however many years of your life, she told Vox. My internal medicine residency is about three years long, but for someone in neurosurgery, it could be seven years.

For many young people, the pandemic has solidified their commitment to working in health care, even as it adversely impacts their career progression. The ongoing public health crisis might seem to benefit hospitals, or at the very least, job prospects for those in the medical industry. That couldnt be further from the current reality, and young, entry-level workers are often the first to witness that.

The coronavirus has led many to reassess the risks and sacrifices that come with the job, and how consequential health care will be in a post-pandemic world. Simultaneously, people are recognizing the longstanding weaknesses and inequalities of Americas medical system. Prospective and current medical school students, too, have become concerned about issues of access and equality, in their field of study and their programs.

Theyve also had to confront the paradoxes emerging in medicine: Health care workers are more necessary than ever, but working nurses and doctors are on the verge of burnout amid the months-long third surge of infections. As of late January, more than 100,000 patients are currently hospitalized across the country with Covid-19. Hospitals, especially those in major metropolitan areas, are overcrowded and short-staffed.

Despite the deluge of patients, medical workers have had to contend with hiring freezes, layoffs, contract negotiations, and shortage of personal protective equipment. About 1.4 million health care jobs were lost in April 2020, and while employment has recovered as states opened back up, the pandemic placed enduring strain on how the US health care system operates.

Young adults in the health care industry or those preparing to enter it are aware theyre at the foot of the ladder. Many college graduates take on low-paying or volunteer roles in clinics and hospitals, and might not even receive priority for vaccines. (At Stanford, nearly all of its medical residents and fellows, who regularly treat Covid-19 patients, did not receive vaccine priority.) On the other hand, medical students eager for patient experience have lost out on clinical opportunities. Medical school applicants, residents, clinic assistants, and nursing graduates recognize how entry-level jobs are harder to come by across the board, and for many, the lesson of the pandemic is learning to settle for less-than-ideal positions to guarantee employment.

Briana, a former medical assistant from Phoenix, Arizona, felt that the pandemic was a sudden but necessary reality check for her career. Briana, who asked to not publish her last name out of privacy concerns, is immunocompromised and works for a clinic that primarily serves the Native American population in Arizona. However, her transition from a patient-facing position to a departmental role took two months, and she felt pressured to be in the office or risk losing her job.

I felt that [my managers] didnt really care that I had an autoimmune disorder, Briana told Vox. They obviously should care more about the patients, but if they dont have any healthy employees, then theyre not going to be able to treat them.

For Jasmine Wong, a recent graduate and working nurse in the Bay Area, risk was top-of-mind while she was interviewing for openings. I asked during my interviews with different hospitals if there was enough PPE provided, she said. Navigating the job hunt during Covid was already very difficult because hospitals were on hiring freezes, and many just didnt have a budget to train new nursing grads.

While most job interviews were conducted over Zoom, a departure from traditional norms, Wong felt that the roles were competitive, especially for nursing positions in adult ICUs. In pre-pandemic times, cinching a job after nursing school depended on a persons professional network relationships at hospitals theyve previously volunteered at. Despite Wongs volunteer work at UCLA Medical Center, the hospital wasnt hiring, and she eventually accepted an offer in a pediatrics ICU elsewhere.

I feel like about 75 percent of people I know from our program have found jobs, but I dont think people got positions they necessarily wanted, she said. Most of us didnt have ICU experience, so it was difficult to compete with those who do. Some of her peers are in non-hospital settings, and some are swabbing at local Covid-19 testing sites.

Funding from Congress has provided some relief for hospital systems across the country, but many are losing money as a result of halting elective surgeries. According to the Washington Post, monthly patient revenue has declined by tens of millions of dollars, and many were already losing money on patient care prior to the pandemic. There is this conception that nurses are needed, but many want experienced nurses and not new graduates, Wong said.

Meanwhile, medical school admissions officers are boasting record-level increases in applicants. They are attributing renewed national attention toward health care to the coronavirus pandemic, dubbing the phenomenon the Fauci effect. (The Association of American Medical Colleges did not share specific figures with Vox, but said that applications are 18 percent higher than they were at this time last year.)

Some applicants, however, say the pandemic has thrown a wrench in a time-intensive and financially draining process. They are challenging the premise that it had any significant effect on present-day admissions, and that its highly improbable for people to apply to medical school on short-term notice.

I spent two years saving up money to take three months off work and to afford the application fees, said Erica Crittendon, who received an offer from the University of Washington. She applied to 28 schools and invested thousands of dollars into the process, which she described as one of the most grueling periods of her life. Crittendon was simultaneously reeling from several Covid-19 losses in her family, and as a Black applicant, felt affected by the summers protests over police brutality.

A person needs to be incredibly privileged to pull off a last-minute application, she told Vox. The pandemic narrative is just highlighting privileges that are detrimental to medicine and health equity.

Rachel Lutz, a University of Oregon graduate who is awaiting an offer, said that her MCAT exam was rescheduled and canceled several times between March and August, which delayed her application. Schools werent consistent about dropping the MCAT exam requirement, which meant most applicants needed to still take the exam to apply to a range of programs.

Lutzs clinical opportunities were canceled, and she moved in with her parents to save money. Applying was very stressful and upsetting at times, but I was privileged in that I didnt have to seriously consider not going through with it, she told me. I dont think taking another gap year would outweigh future earnings for me, but I know people had to make that tough decision.

Some say the circumstances of the pandemic and the lack of leniency from admissions officers and schools have excluded hundreds of prospective applicants. According to the advocacy group Students for Ethical Admissions, only those with significant amounts of financial privilege and economic support can manage to apply amid the many changes in the process.

There are many students who are now lost to the application process, a spokesperson for SEA told Vox. Thats a loss of diversity, of competent and capable individuals, just because the application process was so woefully mismanaged. The Association of American Medical Colleges published a response addressing applicants concerns in July, but students felt that the acknowledgment changed little about the process. The pipeline in medicine is already very leaky, said the SEA spokesperson. Its disappointing that this year, the academic medicine community seems to have shrugged its shoulders.

The applicants and health care workers who spoke with Vox firmly believe that medicine is their vocation. Yet, the coronavirus has stymied their pursuits at almost every level, from delaying licensing exams and required tests to eliminating opportunities for key clinical work that would aid their job search. The pandemics lasting effects on their careers and livelihoods wont easily be forgotten.

Support Vox's explanatory journalism

Every day at Vox, we aim to answer your most important questions and provide you, and our audience around the world, with information that empowers you through understanding. Voxs work is reaching more people than ever, but our distinctive brand of explanatory journalism takes resources. Your financial contribution will not constitute a donation, but it will enable our staff to continue to offer free articles, videos, and podcasts to all who need them. Please consider making a contribution to Vox today, from as little as $3.

See the original post here:
Covid-19 disrupts plans of medical school students and young health care workers - Vox.com

Academic medical institutions address issues of vaccine hesitancy through research and outreach – Inside Higher Ed

Donald Alcendor, an associate professor of microbiology and immunology at Meharry Medical College, a historically Black medical school in Nashville, Tenn., is studying an antiviral treatment for COVID-19 in his lab. But his work isnt confined to the lab: hes also community liaison for Meharrys Novavax vaccine trial. In that role he goes out to businesses, barbershops and beauty salons frequented by African Americans and Latinos to talk to community members about the COVID-19 vaccines and answer their questions in what he describes as a transparent and culturally competent way.

Theres a fair amount of vaccine hesitancy out there, particularly among brown and Black communities, said Alcendor, who is Black. They want their questions answered, and they want their questions answered by someone who looks like them, if you know what I mean. The idea is Meharry Medical College is an important place to do just that -- to answer their questions and to provide them with a vaccine or be part of a vaccine trial.

Academic medical institutions and public health schools, including minority-serving institutions like Meharry, are taking leading roles in confronting vaccine hesitancy in minority communities. African Americans, Latinos and Native Americans are far more likely to contract COVID-19 and to die if they do compared to their white counterparts. Black Americans are 1.4 times more likely than white Americans to contract COVID, 3.7 times more likely to be hospitalized and 2.8 times more likely to die from it. Latinos are 1.7 times more likely to contract COVID, 4.1 times more likely to be hospitalized and 2.8 times more likely to die.

But as the first two COVID vaccines from Pfizer and Moderna have become available, members of underrepresented minority communities report higher rates of vaccine hesitancy. New data released last week by the Kaiser Family Foundations COVID-19 Vaccine Monitor project show that while the share of people who want to get vaccinated as soon as possible has increased across different racial and ethnic groups since December, it is still substantially higher for white adults (53percent) compared to Black (35percent) and Hispanic adults (42percent).

Other data from a multi-university research group finds that Black and Hispanic survey respondents are more likely to believe misinformation about the vaccine, and are more likely than Asian Americans and whites to believe that certain false statements about the vaccine -- for example, that it contains microchips that can track people -- were accurate.

Experts point to a wide range of reasons for higher rates of vaccine hesitancy among Blacks and Hispanics, including the medical professions sorry legacy of mistreatment of Black people, the fear vaccination could be used for immigration enforcement purposes and the inequities minority communities continue to face in terms of access to health care.

David M. Carlisle, the president of the Charles R. Drew University of Medicine and Science, a historically Black graduate institution in Los Angeles, said he was struck by how often laypeople cite the unethical Tuskegee syphilis experiments performed on Black men between 1932 and 1972 as cause for concern.

Its only natural that communities of color that have been underserved by the health-care system would be suspicious about something new, Carlisle said. In December, Carlisle joined with the presidents of the nation's other three historically Black medical schools, along with the presidents of the National Black Nurses Association and the National Medical Association and others, in signing A Love Letter to Black America, affirming respect for Black lives and urging Black Americans to join us in participating in clinical trials and taking a vaccine once its proven safe and effective.

Our community is being ravaged disproportionately by COVID-19, said Carlisle. This is a situation thats very personal, and thats why we want to assure people that the way we can beat back COVID-19 is by optimizing participation in vaccination programs to the fullest extent possible.

"This is really about saving our lives," said Anita Jenkins, CEO of Howard University Hospital, in Washington, D.C. "Too many of us have died."

Howard created a public service announcement about the vaccines aimed at Black Americans. Across the country, academic medical professors and leaders and public health scholars are engaged in advocacy, outreach and research on the issue of vaccine hesitancy.

A research initiative at the City University of New York Graduate School of Public Health & Health Policy, CONVINCE USA, is seeking to better understand and address public concerns about COVID-19 in order to better inform the development of communication and outreach strategies.

"Clarity and transparency and consistency in the message is very important," said Ayman El-Mohandes, the dean CUNY's public health graduate school. "We have found that in many instances people are less certain of accepting a message if there are conflicting messages and if they feel like decisions are being made without full transparency and without the community understanding the science base or the evidence base."

Health professionals routinely emphasize the importance of working with community groups and religious and political leaders to get the message out. The University of Texas Health Science Center at Houston held an event last weekend at one of its clinics in a largely minority community, livestreamed on Facebook, where a number of elected officials received vaccines.

We have to build on the relationships we have with many respected leaders in the community and use them as partners to help educate the community, said LaTanya Love, interim dean of education of McGovern Medical School at the University of Texas Health Science Center at Houston and executive vice president of diversity for UTHealth. We did an event with former heavyweight boxer champion George Foreman; he received his vaccine at one of our clinics. It was a way to use a well-respected celebrity figure in the community to reassure people who are hesitant.

Shiva Bidar-Sielaff, vice president and chief diversity officer for UW Health, the academic medical institution for the University of Wisconsin, said the health-care center has partnered with community groups to organize conversations about the vaccines with doctors who are trusted in the Black and Latino communities.

"Making sure this information is given by trusted sources within the community itself is really critical," Bidar-Sielaff said. She added that the health-care system is in the process of hiring COVID vaccine patient educators to reach out directly to primary care patients, including two each who will focus on Black and Latinx patients and one who will target to Hmong patients.

"It boils down to what we call right message, right messenger work," said Virginia Davis Floyd, an associate professor of clinical community health and preventive medicine at the school of medicine at Morehouse University, a historically Black institution in Atlanta. The medical school received a $40million federal grant to coordinate a network of national, state, territorial, tribal and local organizations to deliver COVID-19-related information to racial and ethnic minority communities who are being hardest hit by the pandemic.

"We have to be consistent with our messaging, and we have to be out there for the long term," said Amelie G. Ramirez, professor and chair of the Department of Population Health Sciences at the University of Texas Health Science Center at San Antonio, a Hispanic-serving institution, and director of the Institute for Health Promotion Research there.

"For the long term, this is an issue we cant ignore," Ramirez said. "COVID has just put a spotlight on health disparities. We need to look to the future and look at what does systemic racism look like in our health-care system and what can we do to improve that so we can provide more equitable health care to our entire population?"

Link:
Academic medical institutions address issues of vaccine hesitancy through research and outreach - Inside Higher Ed

‘A Lot Of Stress’: Medical Student Shares Her Experience Through The Pandemic – 90.5 WESA

Breanna Ngyuen, 27, a medical student at the University of Pittsburgh School of Medicine, had just finished her second year of medical school coursework when the coronavirus pandemic took hold last spring.

Nguyen, of Orlando, FL, had been preparing to enter what many consider one of the most challenging and important years of the medical school journey, when students have several exams and complete clinical work in order to graduate.Instead, Nguyen decided to take a year off and conduct outside research because all in-person instruction and testing centers closed.

I know this caused a lot of stress for me and many of my classmates, and this was definitely one of the biggest challenges as a medical school student during the pandemic, Nguyen said.

Ngyuen says one of the things she misses most about in-person instruction was getting to interact with patients and classmates. Because Ngyuen is taking a year off, shes no longer in the same graduating class as when she began her medical school career.

With COVID and rotations together, it can get really isolating," Ngyuen said.

Ngyuen has been able to conduct in-person research at the Biomedical Science Tower in Oakland since the facilitys reopening in June, but the work requires physical distancing, temperature checks upon entering the building, and lots of sanitization.

Despite the hardships so many medical students have faced through the pandemic, Ngyuen said she's optimistic.

Overall Im extremely impressed with how adaptable everyone has been and how well people have been adhering to guidelines and so that we can keep each other safe," she said. "And progress our research at the same time. My research year has been really rewarding thus far, and Im looking forward to continuing out the year in the lab and returning to rotations in the late spring and summer."

Read the original:
'A Lot Of Stress': Medical Student Shares Her Experience Through The Pandemic - 90.5 WESA

What’s up, doc? Advice for aspiring medical professionals – The Gazette: Eastern Iowa Breaking News and Headlines

Being a doctor or another front line health care worker is a tough job, especially in the last year. But health care workers have been an inspiration during this unprecedented pandemic.

Just in case theyve gotten you thinking about becoming a doctor one day, we asked two doctors at the University of Iowa Hospitals and Clinics to share some advice for aspiring docs.

Its important to remember youll have to spend several years in school before becoming a doctor, first in medical school and then training in a specific field of medicine. Patients expect their doctors to have the knowledge and skills to care for them.

But the key is a love of learning, said Dr. Ericka Lawler, orthopedic surgeon. If youre willing to work hard and spend a lot of time studying, then you can be successful, she said.

Its equally important doctors be compassionate and be able to build good relationships with their patients, said Dr. Sharon Beth Larson, a cardiothoracic surgeon.

In medicine, it truly is not only preserving but improving the quality of life for your patient, Larson said.

Nowadays there are plenty of opportunities to subspecialize in a field of medicine. For example, you dont just have to be a heart doctor. You can be a heart doctor for children, or you can specialize in heart transplants.

You dont have to know what youre interested in right now. Larson said medical school will expose students to many different fields they might not have considered before, both in hospital and clinic settings.

Anyone interested in health care should take advantage of volunteer opportunities at hospitals or nursing homes, or opportunities to shadow doctors on the job. Students also can explore the field through STEM programs offered at schools or through colleges and universities.

Even if it turns out you dont want to be an MD, there are many different jobs in health care and numerous careers that use science and medicine that might catch your eye.

Comments: michaela.ramm@thegazette.com

Excerpt from:
What's up, doc? Advice for aspiring medical professionals - The Gazette: Eastern Iowa Breaking News and Headlines

Shelton joins Huntsville Regional Campus as first-ever director of Research – UAB News

The School of Medicines Huntsville campus will expand the availability of clinical trials for residents of northern Alabama.

Richard C. Shelton, M.D.Internationally recognized physician-scientist Richard C. Shelton, M.D., is joining the Huntsville Regional Medical Campus of the UAB School of Medicine as its first director of Research, a new position to help establish clinical investigation and clinical trials in Huntsville.

Shelton is the Charles Byron Ireland Professor in the Department of Psychiatry and Behavioral Neurobiology and founding director of the UAB Depression and Suicide Research Center. He joins the Huntsville campus March 1, 2021, as a professor of psychiatry and will continue to serve as director of the research center in Birmingham.

In Huntsville, Shelton will launch a new research affiliate of the Depression and Suicide Research Centers clinical trials program, which will bring new treatment interventions and therapeutic options to patients in Huntsville and north Alabama.

After establishing the program in psychiatry, campus leaders hope to expand the research enterprise to create a network of affiliated research sites in Alabama that will conduct research across a range of medical disorders.

We are excited to welcome Dr. Shelton and his wealth of knowledge to the Huntsville campus, said Roger Smalligan, M.D., dean of the Huntsville Regional Medical Campus. His expertise in psychiatry, along with his depth of experience developing and operating successful research programs, will be an incredible resource for north Alabama.

Shelton has over 35 years of research program experience, spending 26 years at Vanderbilt University before joining UAB in 2012. He and his colleagues have had more than 130 research studies funded by the National Institutes of Health and other federal agencies, along with foundations and industry.

Sheltons research focuses on the development of new ways to treat and prevent depression and suicide. This work includes testing new treatments, prevention of serious mental illnesses and suicide, and identifying biomarkers of both disease and treatment response. Recent research studies include participating in two large-scale pharmacogenomics trials that study the effectiveness of ketamine and esketamine intranasal treatment in patients with resistant depression.

Huntsville is the most rapidly growing region in Alabama, and theres relatively little clinical medical research happening in the outpatient environment, Shelton said. With the growing population, there are needs we can address through clinical research. The presence of clinical trials will provide patients access to treatments and tests otherwise unavailable.

Shelton attended medical school at the University of Louisville in Kentucky. He was then a resident at a Harvard Medical School-affiliated hospital in Boston. After residency, he was a research fellow at the National Institutes of Health Intramural Program in Washington, D.C., before joining the faculty of Vanderbilt University School of Medicine.

Clinton Martin, M.D., regional chair of Psychiatry in Huntsville, says recruiting Shelton to the Huntsville campus will not only enhance the clinical research and patient care in Huntsville, but also enhance medical training. The campus trains third- and fourth-year medical students and is home to the Huntsville Internal Medicine Residency and Family Medicine Residency programs.

More here:
Shelton joins Huntsville Regional Campus as first-ever director of Research - UAB News

Survey finds doctors have negative perception of patients with disability – Harvard Gazette

More than 80 percent of U.S. physicians reported that people with significant disabilities have worse quality of life than nondisabled people, an attitude that may contribute to health care disparities among people with disability, according to recent research published in the February issue ofHealth Affairs.

The first-of-its-kind study surveyed 714 practicing physicians from multiple specialties and locations across the country about their attitudes toward patients with disabilities.

That physicians have negative attitudes about patients with disability wasnt surprising, said Lisa I. Iezzoni, lead author of the paper and a health care policy researcher at Harvard-affiliated Massachusetts General Hospital (MGH). But the magnitude of physicians stigmatizing views was very disturbing.

For more than 20 years, Iezzoni has studied health care experiences and outcomes of people with disability and is herself disabled by multiple sclerosis diagnosed in 1980, her first year in medical school.

Only 40.7 percent of surveyed physicians reported feeling very confident about their ability to provide the same quality of care to patients with disabilities as their other patients received. And just 56.5 percent strongly agreed that they welcomed patients with disabilities into their practices. The physicians who reported being most welcoming to patients with disability were female and practiced at academic medical centers. The Americans with Disabilities Act of 1990 requires that people with disability receive equitable health care.

That most surveyed physicians did not give socially desirable answers about their perceptions of people with disability indicates their certainty in their beliefs, said Iezzoni. We wouldnt expect most physicians to say that racial or ethnic minorities have a lower quality of life, yet four-fifths of physicians made that pronouncement about people with disabilities. That shows the erroneous assumptions and a lack of understanding of the lives of people with disability on the part of physicians.

Our results clearly raise concern about the ability of the health care system to ensure equitable care for people with disability, added senior author Eric G. Campbell, professor of medicine and director of research for the Center for Bioethics and Humanities at the University of Colorado Anschutz Medical Campus.

Studies of people with disability show that most dont view their lives as tragic.

Lisa I. Iezzoni

The paper cites examples from Iezzonis and others research demonstrating that individuals with disabilities often receive inferior care. Many surgeons assume, for example, that women with early-stage breast cancer who use wheelchairs want a mastectomy instead of breast-conserving surgery, believing that women with disability dont care about their appearance. And during the surge of the COVID pandemic in March, when resources such as ventilators were scarce, the Office for Civil Rights at the U.S. Department of Health and Human Services felt compelled to issue a warning to health care providers that people with disabilities should not be denied medical care on the basis of disability or perceived quality of life.

The research is a wake-up call for physicians to recognize their biases so they dont make erroneous assumptions about the values of patients with disability, thereby limiting their health care options and compromising care, said Iezzoni, a professor of medicine at Harvard Medical School.

Studies of people with disability show that most dont view their lives as tragic, she added. Theyve figured out how to get around in the world that wasnt designed for them and view their lives as good quality.

The authors call for all levels of medical education, including continuing education for practicing physicians, to include training about disability. Currently, most medical schools dont include disability topics in their curricula. Implicit Association Tests (which measure unconscious bias) related to disability can also raise physicians awareness of how their perceptions about disability may be affecting how they practice medicine.

In future research, the investigators plan to explore the extent to which physicians perceptions about people with disability contribute to disparities in care, said Campbell. Our ultimate goal is to ensure equality in care for people with disabilities.

Funding for this research was provided by the Eunice Kennedy Shriver National Institute for Child Health and Human Development.

Go here to read the rest:
Survey finds doctors have negative perception of patients with disability - Harvard Gazette

Join us for a panel discussion on the COVID vaccine in the Black, Latino communities in Savannah – Savannah Morning News

Savannah Morning News| Savannah Morning News

Join us for an open discussion about the facts and myths of the COVID-19 vaccine, featuring local medical professionals and historians.

In-personcapacity will be limited to comply with CDC recommendations. The program will be live-streamed at facebook.com/savannahnow and savannahnow.com.

You canRSVP herefor the event.

Participants:

Moderators:Rana L. Cash, Savannah Morning News; Tanya Milton, Savannah Tribune

DanielBrownparticipated in the COVID vaccine clinical trials that made the emergency approval of the vaccine possible. He isan emeritus member of the 100 Black Men of Savannah.

Dr. Bonzo Reddick, a Savannah native and son of Judge Bonzo and Betty Reddick, is a 1994 graduate of Windsor Forest High School. A graduate of Morehouse School of Medicine, Reddick is a primary care physician at JC Lewis Health Center. He is also on the faculty in theDepartment of Family Medicine at Mercer Medical School at Memorial.

Dr. Cecil Bennettis a family practice physician at Newnan Family Medicine Associates. A graduate of Morehouse School of Medicine, Dr. Bennett has served on the Board of Trustees of the Georgia Academy of Family Medicine. He was a recent presenter for the African American Newspaper organization to warn of the danger of COVIDs and to provide information on the coronavirus vaccine.

Beatriz Seversonis a registered nurse and advocate for Hispanic communities in Savannah. She serves as a community volunteer for the Coastal Georgia Indicators Coalition, Health and Mental Health Teams; the Savannah Prevention Coalition, under the leadership of Beyond the Bell; and HOLA, a task force created by Savanah Mayor Van Johnson.

Tammi Brownworks for the Georgia Department of Health as the Chatham County Nurse Manager. She was integral to setting up and managing the successful COIVD testing program at the Savannah Civic Center and was among the first people in Georgia to receive the Pfizer vaccine when it became publicly available in the state.

Dr. Karla-Sue Marriottserves as Interim Chair of the Chemistry and Forensic Science Department at Savannah State University. Dr. Marriott has studied the history of vaccines around the world and its effects in communities of color.

This event is presented by the Savannah Morning News, Savannah Tribune, E-93 and Magic 103.9.

View post:
Join us for a panel discussion on the COVID vaccine in the Black, Latino communities in Savannah - Savannah Morning News

Wharton Undergraduate Healthcare Conference addresses impact of COVID-19 on health care – The Daily Pennsylvanian

(Photo from Hannah Gross)

This year's Wharton Undergraduate Healthcare Conference focused on the impact of COVID-19 on the health care industry, featuring speakers from Moderna and NewYork-Presbyterian.

The conference, titled Healthcare in the Wake of COVID-19: The Future of a Changing Industry, took place virtually on Jan. 30. The event included keynote addresses from NewYork-Presbyterian Executive Vice President and Chief Operating Officer Laura Forese and Moderna Chief Medical Officer Tal Zaks, as well as four panels: Health Disparities & Inequities, The Future Of Health Coverage, Outbreaks Of Disease, and Digital Health.

Panelists included legal, medical, and policy experts from a variety of universities and health systems, who shared their experiences with COVID-19. Speakers also addressed the potential long-term impacts of the pandemic on the United States' healthcare system, including an increase in the prevalence of telemedicine, the confrontation of pre-existing health disparities, and the switch to another model of healthcare, such as a single-payer system.

Forese, who oversees operations at 10 hospital campuses in New York, discussed the importance of leadership during the COVID-19 pandemic, focusing on its application to vaccine hesitancy and supply chain coordination. Zaks, a professor of Medicine at the Perelman School of Medicine, discussed the use of mRNA technology in the development of COVID-19 vaccines and other potential uses in healthcare.

During the Outbreaks of Disease panel, panelists discussed the initial response to COVID-19 and attempts to limit its spread.

Abraar Karan, aresident at the Brigham and Women's Hospital and Harvard Medical School, recalled wondering if COVID-19 would be the "next big pandemic" in it's early stages.

"We realized this was going to be really difficult," Karan said. "Its just been a game of trying to stay afloat.

Senior Director of the System-wide Special Pathogens Program at NYC Health + Hospitals Syra Madad said one of the biggest challenges involved adjusting to rapidly changing clinical guidance and resource availability at hospitals.

"Were not used to [the] reuse of PPE, so there was a lot of training that had to go into that, Madad said.

Panelists also discussed how the COVID-19 pandemic impacted all aspects of life, not just health care. Wharton professor Mauro Guilln detailed the pandemic's impact on globalization and business, while Eric Pevzner from the Centers for Disease Control and Prevention's Epidemic Intelligence Service touched on the role of the CDC and the U.S. government in preventing future outbreaks.

Wharton and College junior and WUHC Conference Chair Eric Hsieh said The Future of Health Coverage panel was particularly interesting because of the diversity of fields the panelists came from, including politics, medicine, and law.

Get our newsletter, Dear Penn, delivered to your inbox every weekday morning.

"This led to a back-and-forth discussion about the actual likelihood of a single payer system and about whether employer-sponsored health coverage is sustainable moving forward," Hsieh said.

Despite the virtual format, Conference Committee member and College junior Timothy Lee said WUHC still witnessed high levels of student interaction during the event. Lee said many attendees submitted questions and interacted directly with the keynote speakers, rather than just typing in a Zoom chat.

"It was definitely challenging transitioning to an online Zoom format, while still maintaining the interactive and engaging nature of the WUHC Conference," Lee said. "However, we realized that having this event online opened up a multitude of possibilities in terms of the speakers we could get and who we could market the conference towards.

Here is the original post:
Wharton Undergraduate Healthcare Conference addresses impact of COVID-19 on health care - The Daily Pennsylvanian

‘We’re in a storm’: medical students on the Covid frontline – The Guardian

Abbi Bow, a second-year medical student at the University of Bristol, was just 19 when she began working at one of the citys hospitals on the Covid frontline.

I realise it is a young age to see and work with people on the edge of life, she said. And I do think a lot about the patients I looked after who didnt make it. I remember their names and faces. I dont know if that will ever leave me. Sometimes I see a person in the street who looks like a patient that died and it hits you youre back there with them.

But Bow turns this into a positive. After I become a doctor I will have already been exposed to so much. Learning how to cope with this now will be a benefit in the long term.

When they worked for their A-levels and dreamed of medical school, young people like Bow could not have imagined they would be caught up in a coronavirus crisis.

But more than 500 students from the University of Bristols medical school have donned PPE and worked alongside doctors and nurses in hospitals and GP practices during placements, as volunteers or as healthcare assistants. Many thousands more across the county have done the same.

Bow, now 20, took on a post as a healthcare assistant in April last year and juggles the job with her studies. She works intimately with patients, helping them wash, dress, eat and drink. Some cases stick in her mind.

Quite recently I was helping care for a patient with Covid, said Bow. He was talking but clearly exhausted. His body was tired from fighting Covid. He didnt make it. Its heartbreaking, a very weird experience. Its almost as if the person disappears but the body is still there. His wife is now a widow, his child doesnt have a parent any more.

She helped another patient say goodbye to loved ones via a computer screen because they could not visit. I sat there most of the day holding his hand and playing his favourite music. I was this stranger in full PPE holding his hand but I like to think I brought some comfort.

A third patient Bow worked with was in a coma and looking extremely ill. Then I went in for a shift and she was sat up in bed eating yoghurt. I thought: That cant be the same person. She went over and chatted about the bright pink nail polish the patient was wearing, which her granddaughter had applied before she went into hospital. Its great to think the intervention from us worked and helped her body to fight back. Thats a sweet memory.

Bow remains optimistic. Its sometimes difficult. You wake up and its Groundhog Day. Were not seeing friends and family or going out for dinner or the gym, doing the things we love. Its good to hold on to the idea we will be able to do these things in the future. Once we can, I think well cherish them more.

Luke Ottewell, a 22-year-old fifth year student, has been placed at Gloucestershire Royal hospital helping junior doctors by carrying out tasks such as taking blood samples, inserting cannulas and ordering X-rays.

He was sent home to Spain from university during the first lockdown last spring. But I realised Id rather be here helping out. Ottewell returned in the summer and got stuck in.

Like his fellow fifth years, he has had to balance revision and caring for ill people. His routine as he prepared for his finals was to begin revising at 6.30am, work a 9am-5pm shift at the hospital and then get back to the revision from 5pm-9pm. It has been easier to get out of bed in the morning because of the desire to help out during a national emergency, he said.

Andrew Blythe, the director of the universitys medical programme and a part-time GP, said the students had been exposed to more trauma and stress than most of their predecessors.

Undoubtedly, they are seeing more sicker patients, he said. When they experience death for the first time it is a very powerful and moving experience.

A few have paused their studies because of physical or mental health issues but nobody has dropped out. Their experiences are going to have a profound effect on their whole understanding of medicine. I think for a lot of them the pandemic has motivated them.

Chanelle Smith, another fifth year student aged 22 working with critically ill patients at the Gloucestershire Royal, said her duties ranged from taking bloods to writing discharge summaries. She is about to begin working on the vaccination programme.

Were in a storm, she said. Its hard to remain positive but if we can come through this tunnel well all be so proud. Working in such challenging times makes you stronger. I think its increased my resilience. Its been nerve-racking, humbling, exciting but I feel Im more prepared to be a doctor.

View original post here:
'We're in a storm': medical students on the Covid frontline - The Guardian

The media falsely claims schools are safe: What the science actually says (Part two) – WSWS

This is the second part of a two-part article rebutting a commentary published in the Journal of the American Medical Association (JAMA) Viewpoint, which claims school reopenings are safe. Part One can be read here.

The authors of the JAMA article could have also referenced recent news reports from Austin, Texas, that found positivity rates in schools had climbed over 20 percent. A study conducted by researchers in Michigan and Washington state found that when community infections were low, reopening schools did not seem to make the outbreaks worse. However, when infection rates climbed, schools did contribute to community spread.

A physician and public health professor at George Washington University, Dr. Leana Wen, offered a candid assessment, So, there are two issues: One is that we dont have enough contact tracers all across the country. The second problem is that the community prevalence is just so high that its going to be very difficult to sort out where the infections are originating from.

The CDC has acknowledged that most COVID-19 cases are caused by people who are either presymptomatic or asymptomatic but has deliberately failed to connect these findings to the dangers posed by such transmissions in schools.

Part of the answer to this important question was found in a study funded by the US military and published in the New England Journal of Medicine in December involving Marine recruits during quarantine .

A total of 1,848 recruits volunteered to participate in the study. The average age of these recruits was between 18 and 21, which is just older than high school students, making the results relevant to the question of the pandemics course in schools.

Before entering boot camp, the recruits quarantined for two weeks at home and then two additional weeks on a closed college campus. This involved wearing masks, socially distancing and undergoing daily monitoring of symptoms that included temperature checks.

The volunteers had SARS-Cov-2 PCR testing conducted within two days of their arrival, and again on day 7 and day 14, their last day of supervised quarantine. In the first two days, 16 recruits tested positive, but only one had developed symptoms. By the end of the second week, 35 more participants were found to be infected. Of the 51 volunteers that tested positive, only five had symptoms in the week before their test. That means that less than 10 percent of young adults in this well-controlled study presented with any symptoms.

Additionally, no SARS-CoV-2 infections were identified as a result of daily symptom monitoring. These findings have significant relevance to school openings and highlight that even under the best circumstances, identifying cases among young people will be challenging.

One essential factor that the Democrats, the CDC and the bourgeois press keep silent on is that school closures are a crucial mitigating measure to aid in curtailing community transmission. Teachers and students must have safe environments to conduct classes without fear of becoming infected. But the principal reason for school closures is to suppress the transmission of the virus to protect health systems and avoid further loss of life and spread of disease among the population as a whole.

President Biden and his nominee for education secretary, Miguel Cardona, have gone on record to say that school closures would not help mitigate the pandemic. But it is precisely here that the CDC and proponents of school reopening have avoided referencing the following studies delineating the public health benefit of closing educational institutions:

In a JAMA study published last July 29, the authors had found that statewide school closures in the first wave of the pandemic led to a decline in the incidence of COVID-19 of 62 percent per week. Similarly, mortality saw a 58 percent decrease per week. States that closed earlier saw the most significant relative change per week.

According to a study published in Science , looking at various government interventions used against COVID-19, the combination of the closure of schools and universities, limiting gatherings to 10 people or less, and closing most nonessential businesses reduced the reproductive number, R0, to below one. In other words, it led to an overall reduction in the number of infections in the community. Among the interventions listed, school closures and limiting gatherings to 10 people had the highest impact on mitigating the pandemic.

In a Nature study published in November that ranked the effectiveness of worldwide COVID-19 interventions, the cancellation of small gatherings, closure of educational institutions, border restrictions, increased availability of PPE and individual restrictions were statistically significant in reducing the reproductive number, R0.

A German discussion paper published last July that evaluated the effectiveness of school closures and other pre-lockdown COVID-19 mitigations across three countries, Argentina, Italy and South Korea, found that early interventions that included school closures reduced the total number of COVID-19 deaths and helped flatten the epidemic curve. The authors write, Our preferred estimatesthose that in the main analysis are obtained with the smallest root mean squared prediction errorindicate that the interventions prevented 84%, 29%, and 91% COVID-19 deaths in Argentina, Italy and South Korea, respectively, in comparison to a counterfactual projection. These results are robust across different specifications and show that the effectiveness increases the earlier interventions are enacted. ... The later schools were closed nationwide during the course of the pandemic, the lower the effectiveness of this measure.

The argument being put forth by the Biden administration and the Democrats is a deliberately misleading one. When they assert that school closures do little to halt the pandemic, they mean that without all other aspects of non-pharmaceutical interventions in place, school closures will do little to control community spread of the virus. The study published in Science corroborates that by itself, schools are insufficient to bring the reproductive number under one.

That is not an argument for reopening schools, but for making the closure of schools part of a whole-society effort to control the coronaviruss spread. The fight to prevent school reopenings must be conducted with the struggle to implement a lockdown of nonessential businesses, with full income support for all the workers and small business owners affected.

Donate to the WSWS 2021 New Year Fund

Support the only publication that has told the working class the truth about the coronavirus pandemic and advanced an international socialist perspective in response to the crisis.

The rapid developments of new variants of the coronavirus, such as the B.1.1.7 (also known as the UK variant), circulating widely in the US and many other nations, raises significant new problems for fighting the pandemic. The N501Y mutation in the spike protein of the variants has not only made them more contagious, but it also seems it makes the virus more lethal. There is some evidence that they may also be impacting younger people more severely.

Dr. David Strain, a British physician treating COVID-19 patients and an instructor at the University of Exeters medical school, has seen a rise in admissions to hospitals among younger people and women. He found that the average age of admission to the ICUs has declined from December to January.

After many months of genomic stability in the virus, suddenly, three distinct versions of the SARS-CoV-2 virus on three separate continents have independently acquired similar mutations involving their spike protein. According to a new report published in Wired, that pattern is what scientists refer to as convergent evolution, and its a sign of trouble ahead. This means that separate SARS-CoV-2 viruses have acquired similar mutations that help them evade the human immune response. Examples of convergent evolution in nature include such concurrent and independent phenomena as the evolution of flight by bats, birds and insects.

Dr. Stephen Goldstein, an evolutionary virologist, explained that the variants becoming more infectious is a real benefit to them, from the standpoint of their survivability. They have arrived at the same solution to their dilemma at the same time. If random chance created these mutations, it would improve their odds to acquire the ability to invade as many people as possible. However, it appears that there are selective pressures to these mutations which aid the virus to evade a persons immune system. Vaccines could create these selective pressures as well, but they have been introduced too recently in the course of the pandemic to be the dominant factor presently. (See the link to the study: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants .)

According to Dr. Goldstein, The convergent evolution of wilier versions of the virus might just be a consequence of so many poorly managed government pandemic responses, which didnt marshal sufficient resources or inspire the kind of collective action required to not just crush the initial curve, but keep it crushed.

However, as the virus runs rampant and governments attempt to vaccinate the population quickly in ways that violate protocols without containing the epidemic and looking to force schools open, the consequences could well be additional convergent evolutions that produce an extremely virulent strain of the coronavirus.

This danger was stated most succinctly last week by Dr. Katherine OBrien, director for Immunizations, Vaccines and Biologicals at the World Health Organization:

Risk of variants relative to the vaccines is ever greater when the transmission is very high in the communities. Not only because of variants that have occurred but because of the possibility of additional variants emerging under the pressure of vaccines. We have these amazing tools, and the urgency is to deploy them. But we risk something about those tools if we are also not suppressing transmission to the maximum degree possible where those tools can be effective is setting when there is limited transmission. We have to emphasize about the importance of really crushing transmission now while we are rolling out these new vaccines.

The ruling classes see school openings as necessary to maximize surplus value extraction out of the population. As Bidens top economic aide Brian Deese told a Reuters conference last month, We need to get the schools open so that parents can get back to work. The Biden administration and the Democratic Party, backed by the teachers unions and the Republicans, are playing with fire.

The well-being of the community cannot be left in the hands of any government that places the enrichment of the financial oligarchs over its populations well-being. The concerns being raised by teachers and workers worldwide are validated by the science that must guide humanitys struggle to rid itself of an economic system that not only is a dead weight on social progress, but threatens mass extermination on an unprecedented scale. The pandemic is such a scourge, with the contradictions of capitalism blocking a serious, science-driven response that prioritizes saving lives, not corporate profit.

View original post here:
The media falsely claims schools are safe: What the science actually says (Part two) - WSWS

Florida optometrists push for expanded treatment options, but ophthalmologists arent having it – The Capitolist

A turf war has reignited in Tallahassee between optometrists and ophthalmologists over two newly filed bills in the Florida House and Senate.

The proposals, HB 631 in the House and its Senate companion, SB 876would expand the scope of practice for optometrists to allow them to perform limited surgical procedures and prescribe an expanded list of medications specialties that have long been restricted to ophthalmologists, who have undergone several additional years of specialized training.

Its not a new battle. Similar turf wars between the two groups have flared up in the past, with the pro-optometry side arguing that expanding their scope of practice will introduce competition into the health care market and provide Florida residents with more access to professionalized eye care.

But a statewide association of ophthalmologists says the bill is dangerous and should not be passed.

The idea that an optometrist could become licensed to perform surgery through legislation, instead of completing medical school and residency training, is a dangerous threat to patient safety, saidDr.Sarah Wellik, President of the Florida Society Ophthalmologists. With Florida being the epicenter of the opioid epidemic, it would be catastrophic for the Legislature to expand optometrys prescribing authority to over 4,000 non-medical professionals.

The 2021 battle could soon become more intense as lobbyists line up on both sides to advocate for their respective clients. State Senator Manny Diaz Jr. and State Representative Alex Rizo filed the bills in the Senate and House, respectively. Diaz previously filed legislation to expand the optometrist scope of practice when he served in the Florida House.

While both optometrists and ophthalmologists are both considered eye doctors, optometrists typically undergo four years of instruction after undergraduate school in a professional program that trains them to perform eye exams and vision tests, as well as prescribe glasses and contacts, and monitor eye health for diseases like diabetes, glaucoma and dry eye.

Ophthalmologists, by contrast, have gone to three years of medical school after undergrad, after which they participate in a 1-year internship and a residency of 3 years. Those stints are sometimes followed by a 1 to 2 year fellowship program. Ophthalmologists can perform virtually all of the same procedures as optometrists, but can also perform specialized surgeries and generally can provide a higher level of care for more complex eye problems.

The Florida Optometric Association did not immediately respond to a phone call and email seeking comment for this story.

Related

Link:
Florida optometrists push for expanded treatment options, but ophthalmologists arent having it - The Capitolist

The Association Between Smoking and Subarachnoid Hemorrhage – Neurology Advisor

Genetically determined smoking behavior is associated with an increased risk for non-traumatic subarachnoid hemorrhage (SAH), according to study results published in Stroke.

Data suggest that smoking is an important risk factor for aneurysm formation and rupture. While previous studies have identified an increased risk for non-traumatic SAH among smokers, the causal association is not well understood. The objective of this study was to determine if smoking is causally related to the risk for SAH.

Study researchers conducted this large prospective study with Mendelian Randomization analyses using data from the UK BioBank, a large cohort study with over 500,000 adults (age, 40-69 years) from 2006 to 2010. Of the 408,609 patients evaluated, 132,566 (32%) ever smoked regularly and 902 (0.22%) were diagnosed with SAH.

A polygenic risk score that represents the genetic propensity to smoke was built using individual-level genetic data and included 126 single nucleotide polymorphisms.

There was a strong association between genetic susceptibility to smoking with both smoking initiation and risk of SAH. Each additional SD of the smoking polygenic risk score was associated with a 21 percent increased risk for smoking initiation (odds ratio [OR], 1.21; 95% CI, 1.20-1.21; P <.001) and with a 10 percent increased risk for SAH (OR, 1.10; 95% CI, 1.03-1.17; P =.006).

In the primary Mendelian Randomization analysis using the ratio method, genetic susceptibility to smoking was linked to a 63 percent increase in risk of SAH (OR, 1.63; 95% CI, 1.15-2.31; P =.006). The results were similar on secondary Mendelian Randomization analyses using the inverse variance weighted method (OR, 1.57; 95% CI, 1.13-2.17; P =.007) and the weighted median method (OR, 1.74; 95% CI, 1.06-2.86; P =.03).

Findings indicated that the genetic susceptibility to smoking initiation was associated with a 60 percent increase in the risk of SAH, and, compared with never smokers, this increased risk was similar for those who smoked 0.05 to 20 packs per year (OR, 1.63; 95% CI, 1.01-2.62; P =.04), 20 to 40 packs per year (OR, 1.65; 95% CI, 1.13-2.41; P =.009) and more than 40 packs per year (OR, 1.56; 95% CI, 1.08-2.25; P =.02).

The study had several limitations, according to the study researchers, including potential misclassification of the outcome secondary to use of ICD codes to determine SAH cases, the absence of an independent dataset to confirm the results, and the limited demographic of the study population (all genetically determined White study participants). As a result, findings cannot be applied to other racial and/or ethnic populations.

We found that a stronger genetic predisposition to smoking is significantly associated with an increased risk of SAH. These findings provide important evidence to support a causal relationship between smoking and the risk of SAH, concluded the study researchers.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Acosta JN, Szejko N, Both CP, et al. Genetically determined smoking behavior and risk of nontraumatic subarachnoid hemorrhage. Stroke. Published online January 14, 2021. doi:10.1161/STROKEAHA.120.031622

More here:
The Association Between Smoking and Subarachnoid Hemorrhage - Neurology Advisor

Alzheimers Prediction May Be Found in Writing Tests – The New York Times

Is it possible to predict who will develop Alzheimers disease simply by looking at writing patterns years before there are symptoms?

According to a new study by IBM researchers, the answer is yes.

And, they and others say that Alzheimers is just the beginning. People with a wide variety of neurological illnesses have distinctive language patterns that, investigators suspect, may serve as early warning signs of their diseases.

For the Alzheimers study, the researchers looked at a group of 80 men and women in their 80s half had Alzheimers and the others did not. But, seven and a half years earlier, all had been cognitively normal.

The men and women were participants in the Framingham Heart Study, a long-running federal research effort that requires regular physical and cognitive tests. As part of it, they took a writing test before any of them had developed Alzheimers that asks subjects to describe a drawing of a boy standing on an unsteady stool and reaching for a cookie jar on a high shelf while a woman, her back to him, is oblivious to an overflowing sink.

The researchers examined the subjects word usage with an artificial intelligence program that looked for subtle differences in language. It identified one group of subjects who were more repetitive in their word usage at that earlier time when all of them were cognitively normal. These subjects also made errors, such as spelling words wrongly or inappropriately capitalizing them, and they used telegraphic language, meaning language that has a simple grammatical structure and is missing subjects and words like the, is and are.

The members of that group turned out to be the people who developed Alzheimers disease.

The A.I. program predicted, with 75 percent accuracy, who would get Alzheimers disease, according to results published recently in The Lancet journal EClinicalMedicine.

We had no prior assumption that word usage would show anything, said Ajay Royyuru, vice president of health care and life sciences research at IBM Thomas J. Watson Research Center in Yorktown Heights, N.Y., where the A.I. analysis was done.

Alzheimers researchers were intrigued, saying that when there are ways to slow or stop the illness a goal that so far remains elusive it will be important to have simple tests that can warn, early on, that without intervention a person will develop the progressive brain disease.

What is going on here is very clever said Dr. Jason Karlawish, an Alzheimers researcher at the University of Pennsylvania. Given a large volume of spoken or written speech, can you tease out a signal?

For years, researchers have analyzed speech and voice changes in people who have symptoms of neurological diseases Alzheimers, ALS, Parkinsons, frontotemporal dementia, bipolar disease and schizophrenia, among others.

But, said Dr. Michael Weiner, who researches Alzheimers disease at the University of California, San Francisco, the IBM report breaks new ground.

This is the first report I have seen that took people who are completely normal and predicted with some accuracy who would have problems years later, he said.

The hope is to extend the Alzheimers work to find subtle changes in language use by people with no obvious symptoms but who will go on to develop other neurological diseases.

Each neurological disease produces unique changes in speech, which probably occur long before the time of diagnosis, said Dr. Murray Grossman, a professor of neurology at the University of Pennsylvania and the director of the universitys frontotemporal dementia center.

He has been studying speech in patients with a behavioral form of frontotemporal dementia, a disorder caused by progressive loss of nerves in the brains frontal lobes. These patients exhibit apathy and declines in judgment, self control and empathy that have proved difficult to objectively quantify.

Speech is different, Dr. Grossman said, because changes can be measured.

Early in the course of that disease, there are changes in the pace of the patients speech, with pauses distributed seemingly at random. Word usage changes, too patients use fewer abstract words.

These alterations are directly linked to changes in the frontotemporal parts of the brain, Dr. Grossman said. And they appear to be universal, not unique to English.

Dr. Adam Boxer, director of the neurosciences clinical research unit at the University of California, San Francisco, is also studying frontotemporal dementia. His tool is a smartphone app. His subjects are healthy people who have inherited a genetic predisposition to develop the disease. His method is to show subjects a picture and ask them to record a description of what they see.

We want to measure very early changes, five to 10 years before they have symptoms, he said.

The nice thing about smartphones, Dr. Boxer added, is that you can do all kinds of things. Researchers can ask people to talk for a minute about something that happened that day, he said, or to repeat sounds like tatatatata.

Dr. Boxer said he and others were focusing on speech because they wanted tests that were noninvasive and inexpensive.

Dr. Cheryl Corcoran, a psychiatrist at Icahn School of Medicine at Mount Sinai in New York, hopes to use speech changes to predict which adolescents and young adults at high risk for schizophrenia may go on to develop the disease.

Drugs to treat schizophrenia may help those who are going to develop the disease, but the challenge is to identify who the patients will be. A quarter of people with occasional symptoms saw them go away, and about a third never progressed to schizophrenia although their occasional symptoms persisted.

Guillermo Cecchi, an IBM researcher who was also involved in the recent Alzheimers research, studied speech in 34 of Dr. Corcorans patients, looking for flight of ideas, meaning the instances when patients were off track when talking and spinning off ideas in different directions. He also looked for poverty of speech, meaning the use of simple syntactic structures and short sentences.

In addition, Dr. Cecchi and his colleagues studied another small group consisting of 96 patients in Los Angeles 59 of whom had occasional delusions. The rest were healthy people and those with schizophrenia. He asked these subjects to retell a story that they had just heard, and he looked for the same telltale speech patterns.

In both groups, the artificial intelligence program could predict, with 85 percent accuracy, which subjects developed schizophrenia three years later.

Its been a lot of small studies finding the same signals, Dr. Corcoran said. At this point, she said, we are not at the point yet where we can tell people if they are at risk or not.

Dr. Cecchi is encouraged, although he realizes the studies are still in their infancy.

For us, it is a priority to do the science correctly and at scale, he said. We should have many more samples. There are more than 60 million psychiatric interviews in the U.S. each year but none of those interviews are using the tools we have.

Here is the original post:
Alzheimers Prediction May Be Found in Writing Tests - The New York Times

COVID-19 can hide in the brains of mice, cause neurological issues – Business Insider – Business Insider

Darius Settles was sent home from the emergency room twice after contracting COVID-19 in June. The first time, he was told to come back if his condition worsened. On his second visit, his blood-oxygen levels were normal enough to discharge him again. He died in July, the youngest person killed by the coronavirus in Nashville, Tennessee, at that time.

Situations in which patients seem better, get discharged, then see their conditions worsen, have become common over the course of the pandemic. New research suggests it may be related to infections in the brain.

"People seem to have very nice recovery, lung functions are fine, and we send them home just to find out that three days later, the patient becomes so severe that they died," Mukesh Kumar, a virologist at Georgia State University, told Insider. "That usually can only happen when the brain is involved."

Kumar recently published a study in the journal Viruses that examines how COVID-19 affects the brains of mice.

His results showed that three days after the mice were infected with the coronavirus, they displayed high levels of virus in their lungs. By days five and six, their lungs had started to clear up but their brains showed about 1,000 times more virus than the peak levels found in the lungs. That coincided with the arrival of severe symptoms such as labored breathing, disorientation, and weakness.

The virus also triggered an inflammatory response in the brain, marked by the release of chemical signals called cytokines. Under normal circumstances, cytokines tell the immune system to fight off infection but too many cytokines can instruct the body to attack its own cells, triggering dangerous levels of inflammation. The mice brains in the study showed around 10 to 50 times more cytokines than the lungs.

In some mice, the reaction caused immediate death. But in mice with milder cases, the virus seemed to hide out in the brain indefinitely.

Though results of mice studies don't always hold true for humans, Kumar suspects that the brain is a major target for the coronavirus.

"Our brain doesn't have that good immune response like our lungs or our heart, so whenever the virus goes in the brain, it can replicate very well," Kumar said. "It can stay there for a long time."

Viral replication in the brain could also explain why some coronavirus patients have persistent neurological issues, such as dizziness or brain fog, long after they've tested negative for COVID-19. In some cases, Kumar said, there's a risk these neurological problems may give rise to chronic illnesses such as autoimmune disorders, Parkinson's, or multiple sclerosis.

"Depending upon your immune response or antibody levels, it could cause low levels of inflammation, or maybe make you prone to other disease, or maybe reactivate later," he said. "All these are still outstanding questions because we are still only one year into the pandemic."

A woman improperly wears her face mask in Rome, Italy, on April 29, 2020. Andreas Solaro/AFP/Getty Images

COVID-19 is often described as a respiratory disease, since the coronavirus attacks the lungs first. But some researchers suspect it may be a vascular disease, given that some patients develop blood clots, leaky capillaries, and inflamed blood vessels, which can lead to heart damage or stroke.

ADutch study of 184 coronavirus patients in the ICU found that nearly one-third of patients had blood clots. And aJuly study of 100 COVID-19 patients found that 78 of them had some degree of heart damage. Studies have also suggested that nearly 2% of COVID-19 patients have strokes far more than than the rate of strokes among influenza patients.

But Kumar's study didn't detect any virus in the blood of infected mice.

Instead, his research showed that the virus entered the brain through the nasal passages, before attacking the central nervous system. Part of that nervous system controls our sense of smell, which may explain why many coronavirus patients have trouble smelling. Kumar said it's possible that the virus could reach the brain after entering the mouth as well, but the nose is a more direct pathway.

In mice, the coronavirus seemed to have trouble replicating in organs such as the heart, liver, or kidneys. But an infection in the brain can ultimately damage such organs, Kumar said.

"It doesn't even have to go to every organ, because if it can go to the brain, there are several parts of the brain that control all other organs," he said. "So it could also be possible that you don't even need virus in the lungs to cause lung failure."

A patient who has recovered from COVID-19, gestures next to his son as he leaves the Juarez Hospital in Mexico City, Mexico, July 27, 2020. Edgard Garrido/Reuters

Neurological issues are more common among coronavirus patients than scientists originally thought.

An October study found that 82% of coronavirus patients admitted to a hospital network in Chicago in March and April 2020 had neurological symptoms. The issues ranged from relatively minor headaches, dizziness, and loss of smell to serious conditions like brain damage, strokes, and seizures.

In some cases, these symptoms can linger for at least several months.

A recent study from University of Oxford researchers, which is still awaiting peer review, found that 13% of people who got COVID-19 were diagnosed with a psychiatric or neurological illness within six months of testing positive for the virus. Some patients even showed signs of Parkinson's disease or Guillain-Barr syndrome, a rare autoimmune disorder, but those results weren't statistically significant.

Kumar said it's fairly simple to tell whether a patient has a severe neurological condition, since the issue will likely show up on an MRI or CT scan. But mild neurological problems are often difficult to pinpoint.

"Unfortunately, based on other studies, it could be lifelong," Kumar said. "We know patients who are still showing symptoms who were infected a year ago."

The research he did on mouse brains, however, is difficult to replicate in humans.

"The patient has to die to actually find out if the virus is hiding in the brain," he said.

Originally posted here:
COVID-19 can hide in the brains of mice, cause neurological issues - Business Insider - Business Insider

Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets – Daily Local…

EXTON, Pa., Jan. 29, 2021 /PRNewswire/ --Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering, Launch Dynamix. This innovative, independent service provides monthly benchmarking of newly launched products for the first eighteen months of commercial availability.

This is augmented by a quarterly deep dive into promotional activity, messaging, drivers of use, barriers to uptake, patient types, market access landscape, and degree of disruption surrounding the newly launched product including a mix of both quantitative and qualitative feedback. Clients subscribed to this service received their first monthly pulse on January 15, 2021, including data benchmarking the current launch to relevant historical market entrants at similar post-entry timings.

In rheumatology, Spherix is currently tracking the entry of both Novartis' Cosentyx and Eli Lilly's Taltz in non-radiographic axial spondylarthritis (nr-axSpA), which were approved within weeks of each other in June of last year. Data on the key performance indicators (KPIs), provided in the January publication, are compared to the performance of UCB's Cimzia, which was the first biologic/advanced systemic agent to gain FDA approval for nr-axSpA in March of 2019.

With regard to psoriatic arthritis (PsA), Spherix's new service is available for Janssen's Tremfya, with KPIs benchmarked to Cosentyx, Taltz, Amgen's Otezla, and Pfizer's Xeljanz. Pending FDA approval, Spherix also plans to cover AbbVie's Rinvoq in both ankylosing spondylitis (AS) and PsA, Xeljanz for the treatment of AS, and AstraZeneca's anifrolumab for the treatment of systemic lupus erythematosus.

Inaugural Launch Dynamix coverage in gastroenterology includes tracking and trending of Janssen's Stelara for the treatment of ulcerative colitis (UC), benchmarking the entry of the IL-12/23 inhibitor to the respective Crohn's disease launch, as well as the launch of Xeljanz for the treatment of UC.

In neurology, Spherix is currently covering the launches of Novartis' Kesimpta and BMS' Zeposia, with appropriate benchmarked KPIs to Genentech's Ocrevus, Novartis' Mayzent, EMD Serono's Mavenclad, and Biogen's Vumerity. Pending approval, Spherix will also cover the launch of Janssen's ponesimod, which is expected to be available in the Spring of 2021.

In an area of significant unmet need, the lupus nephritis market is poised for a massive shift with recent drug approvals for GSK's Benlysta (also approved for systemic lupus erythematosus) and Aurinia Pharmaceuticals' Lupkynis. The study will include responses from both nephrologists and rheumatologists, with the first pulse available in February.

Other launches on Spherix's radar with planned 2021 coverage (pending approval) include:

"We are really excited to be able to bring this level of launch detail to our clients," says Lynn Price, Vice President of Strategy and Innovation at Spherix. "The rapid turn-around from fielding to publication and the monthly cadence coupled with quarterly deep-dives provides those with assets in this market or with near-term plans to enter it the perfect tool to keep their finger on the pulse."

About Launch Dynamix

Launch Dynamix is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into patient types initiated, brand perceptions, promotional activity, and drivers and barriers to uptake. The service is offered on a brand-by-brand basis.

Learn more about our services here.

About Spherix Global Insights

Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:

Kristen Henn, Business Development Manager

Email:info@spherixglobalinsights.com

http://www.spherixglobalinsights.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-global-insights-introduces-new-service-focusing-on-recent-launches-in-expanding-immunology-nephrology-and-neurology-markets-301217950.html

SOURCE Spherix Global Insights

Go here to read the rest:
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets - Daily Local...

Interventional Neurology Device Market 2021 Industry Scenario, Strategies, Growth Factors And Forecast 2025 | Medtronic, Johnson and Johnson, Terumo…

Big Market Researchstudy on the 2021Interventional Neurology Device Marketis a powerful resource for industry professionals to analyze the Interventional Neurology Device Market deeply and helps in decision making. The report provides a detailed assessment of market size, revenue structure, CAGR, consumption, profit margin, price, and various influencing factors. Also, the report covers new product development, key trends, market drivers, challenges, restraints, competitive landscape, growing technologies, case studies, new business opportunities, future roadmap, value chain, leading key players profiles, and strategies. Interventional Neurology Device report is a completely valuable source of insightful data for making business decisions and competitive analysis of the Interventional Neurology Device Market.

Ask for a Sample PDF Copy of Interventional Neurology Device Market with Figures, Graphs and Tocs:https://www.bigmarketresearch.com/request-sample/4163093?utm_source=McC&utm_medium=MWA

NOTE:Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers postCOVID-19crisis. TheInterventional Neurology Device Marketreport aims to provide an additional illustration of the latest scenario, economic slowdown, andCOVID-19impact on the overall industry.

How will this Market Intelligence Report Benefit You?

The Interventional Neurology Device Market is also characterized by a highly complex value chain involving product manufacturers, material suppliers, technology developers, and manufacturing equipment developers. Partnerships between research organizations and the industry players help in streamlining the path from the lab to commercialization. In order to also leverage the first mover benefit, companies need to collaborate with each other so as to develop products and technologies that are unique, innovative and cost effective.

Talk to our Analyst / Ask for a discount on Interventional Neurology Device Market and Get More Information Related to This Report:https://www.bigmarketresearch.com/request-for-discount/4163093?utm_source=McC&utm_medium=MWA

Key questions answered in this report:

Market players have been discussed and profiles of leading players including Top Key Companies:MedtronicJohnson and JohnsonTerumo CorporationPenumbra, Inc.Merit Medical Systems, IncW.L. Gore & AssociatesMicroport Scientific CorporationMedikit Co., Ltd.Stryker

Get Access of Complete Copy of This Report and Avail Instant 10% of Discount by Using Coupon Code [ORG123WA]:https://www.bigmarketresearch.com/checkout/sales/37169

By the product type, the Interventional Neurology Device Market is primarily split into 2020-2025:Embolization & coilingNeurothrombectomy Devices

By the end-users/application, the Interventional Neurology Device Market report covers the following segments 2020-2025:Treatment of Cerebral AneurysmsTreatment of Cerebral VasospasmVertebroplasty

Geographically, this report is segmented into several key Regions along with their respective countries, with production, consumption, revenue (million USD), and market share and growth rate ofInterventional Neurology Device Marketin the following regions:

Thanks for reading this article you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

You May Also Like Our Other Top Trending Reports:

For More Information Regarding Other Similar Trending Report Click on The Given Link:https://www.mccourier.com/ppm-and-it-governance-market-2021-by-investment-feasibility-sales-production-and-company-introduction-hpe-microsoft-oracle/

Contact us:Mr. Abhishek Paliwal5933 NE Win Sivers Drive, #205, Portland,OR 97220 United StatesDirect:+1-971-202-1575Toll Free:+1-800-910-6452E-mail:help@bigmarketresearch.com

Continue reading here:
Interventional Neurology Device Market 2021 Industry Scenario, Strategies, Growth Factors And Forecast 2025 | Medtronic, Johnson and Johnson, Terumo...

VCA Animal Referral & Emergency Center of Arizona has a neurology department that can treat a variety of conditions – Yahoo News

The Telegraph

Ursula von der Leyen on Monday pinned the blame for the vaccine fiasco that led Brussels to threaten a hard border on the island of Ireland on her trade commissioner Valdis Dombrovskis. The European Commission president threw her deputy, who leads DG Trade, under the bus amid rising anger from EU capitals at her go it alone tactics during last weeks battle with AstraZeneca. Jean-Claude Juncker, Mrs von der Leyen's predecessor, said he was "very much opposed" to her export restriction measures. In a speech in Stuttgart on Sunday, Mr Juncker also said of the EUs vaccine procurement: "It all went too slow, it all should have been done more transparently, even though that would have been difficult." This regulation falls under the responsibility of Mr Dombrovskis, said Eric Marmer, the European Commissions chief spokesman, referring to the former prime minister of Latvia, a Brussels veteran with a reputation for caution. In my country we have a saying, Only the Pope is infallible. Mistakes can happen along the way the important thing is that you recognise them early on, Mr Mamer said. Alexander Stubb, the former prime minister of Finland who campaigned to be appointed European Commission, president was scathing about Mrs Von der Leyen. He said "Number one rule of any leader: if your organisation screws up; never, ever blame your team publicly" Mrs von der Leyen was forced into a humiliating climbdown on Friday after announcing Brussels would trigger Article 16 of the Northern Ireland Protocol, to prevent AstraZeneca vaccines being smuggled into Britain from Northern Ireland. The move, which was announced without notifying Ireland or Britain, would have created a vaccine border after years of Brexit talks to avoid a hard border on the island. After the Irish prime minister called Mrs von der Leyen, the regulation, which could have facilitated a vaccine export ban to non-EU countries including Britain, was amended. Mr Mamer said that the regulation to create an export transparency mechanism, which including the Article 16 measure, was passed provisionally and at speed by the entire College of Commissioners on Friday. Asked by the Telegraph if this was Ms Van der Leyens worst week, he said: We believe that we are on the right track since the beginning of this pandemic in ensuring there is as cohesive and as effective a European response as possible. Mrs von der Leyens attempts to pass the buck cut no ice with EU diplomats, who suggested she had gone rogue, or German MPs in Berlin, who plan to summon Ursula von der Leyen for questioning. In a further blow to Mrs von der Leyen, the move was led by MPs from her own party, Angela Merkel's Christian Democrats (CDU). Mrs von der Leyen has refused calls for a public debate on the debacle in the European Parliament. Instead she will on Tuesday hold closed door meetings with MEPs with parties who approved her appointment. It is understood that Mrs von der Leyen took personal charge of the vaccine row and that DG Trades senior official is Sabine Weyand, whose objections to triggering Article 16 were reported to have been overruled. Ms Weyand is keenly aware of the political sensitivities around the Brexit divorce treatys Northern Ireland Protocol. She was Michel Barniers deputy Brexit negotiator and a key figure in the creation of the Irish border backstop.

More:
VCA Animal Referral & Emergency Center of Arizona has a neurology department that can treat a variety of conditions - Yahoo News

Journal Watch: TXA and Neuro OutcomesMore Than Meets the Eye – EMSWorld

Reviewed This Month

Effect of Out-of-Hospital Tranexamic Acid vs. Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury.

Authors: Rowell SE, Meier EN, McKnight B, et al.

Published in: JAMA, 2020 Sep 8; 324(10): 96174. Erratum in: JAMA, 2020 Oct 27; 324(16): 1,683.

Over the last decade, the use of tranexamic acid (TXA) for traumatic hemorrhage control has increased. This was due to the results of a clinical trial, published in 2010, that found early administration of TXA was a cost-effective way to reduce the risk of death in bleeding trauma patients.

Further research has shown that TXA is safe for patients with traumatic brain injury (TBI). In this months Journal Watch, we review a randomized, double-blind multicenter trial designed to examine the efficacy and safety of out-of-hospital administration of tranexamic acid compared to placebo in participants with moderate or severe TBI who were not in shock.

The objective of this trial was to determine whether TXA administered by EMS within two hours of injury improved neurologic outcome. Read that objective carefullyit will be important when putting the results of this trial into context.

Neurologic outcome was measured using the Glasgow Outcome Score-Extended (GOSE). The authors chose to dichotomize this scale into favorable (which included moderate disability or good recovery) and poor (which included severe disability, vegetative state, or death) outcomes.

The authors also examined many secondary outcomes, including 28-day mortality, six-month disability, progression of intracranial hemorrhage, incidence of neurosurgical interventions, hospital-free days, ICU-free days, incidence of seizures, and incidence of thrombotic events, to name a few.

The study was conducted in 12 regions across the U.S. and Canada. It included 39 EMS agencies and 20 trauma centers. To be eligible for enrollment in this trial, patients had to be at least 15 years of age, with moderate or severe blunt or penetrating TBI, a GCS score of 3 to 12, at least one reactive pupil, a systolic blood pressure of at least 90 mm Hg, and an IV in place prior to randomization.

Participants were randomized into one of three treatment groups. The first received a 1-gram IV bolus of TXA by EMS followed by a gram of in-hospital TXA infused over eight hours. The next group received a 2-gram TXA bolus by EMS followed by a placebo infusion. The final group received an IV bolus placebo by EMS and a placebo infusion in the hospital. Study kits that appeared identical were shipped to participating EMS agencies for placement on EMS vehicles in random order. Each vehicle only carried one study kit at a time.

The study was conducted between May 2015 and March 2017 under U.S. regulations for exception from informed consent and the Canadian tricouncil policy statement on ethical conduct in research involving humans.

There were 966 patients included in the analysis. Their average age was 42, and almost three-quarters (74%) were male. The average GCS score was 8. The three study groups were similar when comparing demographics and baseline anatomic and physiologic characteristics as well as injury severity. However, the authors note there were fewer penetrating injuries in the bolus-only group.

The median estimated time from injury to EMS administration of the study drug ranged from 40 to 43 minutes. The median time from EMS administration to the start of the in-hospital infusion ranged from 86 to 96 minutes.

The evaluation of the primary study outcome, favorable or poor neurologic function, revealed no statistically significant difference when comparing TXA to placebo (65% vs. 62%, p=0.16). Therefore, the conclusion of this study was that among patients with moderate or severe TBI, out-of-hospital tranexamic acid administration within two hours of injury did not improve six-month neurologic outcome as measured by the GOSE.

However, as we discuss often in this column, we should not let statistical significance alone guide our judgment of importance. There was a 3% difference in favorable neurologic outcome. While that difference may not be statistically significant, could it be clinically meaningful?

Now, rather than simply read the objective and conclusion of this paper, lets dive a little deeper. As mentioned earlier, the authors also examined several secondary outcomes. When evaluating 28-day mortality, the TXA groups showed a 3% improvement (14% vs. 17%). This result was also not statistically significant, with a p-value of 0.26.

There was also an 8% difference in 28-day mortality when comparing the bolus-only group to the placebo group for those patients with intracranial hemorrhage. This difference was statistically significant (p=0.03). The total number of adverse events was also similar between groups.

Why would the authors report such a cut-and-dried conclusion when there seems to be a trend favoring the use of TXA? Well, the authors indicate in their methods section that the study was specifically designed to evaluate neurologic outcomes at six months. This was specified in the original trial registry on ClinicalTrials.gov. The authors had to stick to the primary outcome that was specified prior to the beginning of trial enrollment for the resulting manuscript.

However, the authors are clear that we should carefully interpret their findings. They state in their discussion that despite no statistically significant difference in the primary outcome in either trial, there were important differences and findings from both trials that warrant consideration and future investigation.

In other words, the results seem to be trending in a favorable direction when EMS administers TXA early. So, rather than to simply conclude from these findings that TXA is not effective in the treatment of TBI, an important next step would be to design studies that specifically evaluate outcomes other than the dichotomous GOSE score at six months.

As with all studies there are limitations here. There were some difficulties in obtaining follow-up data six months after the injury. This is not surprising, given that patients were enrolled prior to giving consent. There was also a low percentage of patients with intracranial hemorrhage enrolled in the study. This may have diluted the treatment differences.

This was a very well done study that will lead to further analysis of TXA administration. It is also a great example of how we should avoid letting a p-value alone guide our judgment of importance.

I hope you have an opportunity to read the manuscript yourself. There are many other interesting results that could not fit into this months Journal Watch. And, as always, I hope to review your study in an upcoming edition soon.

Antonio R. Fernandez, PhD, NRP, FAHA, is a research scientist at ESO and an assistant professor in the department of emergency medicine at the University of North CarolinaChapel Hill. He is on the board of advisors of the Prehospital Care Research Forum at UCLA.

Read this article:
Journal Watch: TXA and Neuro OutcomesMore Than Meets the Eye - EMSWorld